<DOC>
	<DOCNO>NCT01010581</DOCNO>
	<brief_summary>The purpose study determine efficacy , safety pharmacokinetics SC12267 ( 4SC-101 , 35 mg ) combination methotrexate comparison methotrexate alone treatment patient suffer Rheumatoid Arthritis .</brief_summary>
	<brief_title>SC12267 ( 4SC-101 ) Combination With Methotrexate Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<criteria>Main Patients active RA functional class I , II III accord criterion American Rheumatism Association RA DAS28 ( ESR ) â‰¥ 4.5 ( DAS28 formula 4 variable use ESR ) Patients receive weekly dos MTX ( 1025 mg/week ) minimum 3 month prior Day 1 dosing , receive stable MTX dose 1025 mg/week without change route change folic acid supplementation least 6 week prior Day 1 dose Patients may receive 10 mg/day oral prednisolone steroid equivalent . Dose must stable least 30 day must change washout , screen treatment period , unless dictate tolerability requirement Main Patients RA functional class IV accord criterion American Rheumatism Association RA Patients receive following treatment must abide indicated washout period : 1 . Leflunomide require 6 month washout period prior Day 1 dose 2 . Oral injectable gold , azathioprine , penicillamine , anakinra require 30 day washout period prior Day 1 dose 3 . Cyclosporine , abatacept , etanercept , adalimumab , infliximab , rituximab require 60 day washout period prior Day 1 dose 4 . Cyclophosphamide require 180 day washout period prior Day 1 dose 5 . Parenteral intraarticular corticosteroid require 30 day washout period prior Day 1 dose Receipt follow drug within 4 week prior dose : 1 . Sulfasalazine 2 . Hydroxychloroquine 3 . Use corticosteroid &gt; 10 mg/day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>SC12267</keyword>
	<keyword>4SC-101</keyword>
	<keyword>Methotrexate</keyword>
	<keyword>Phase II</keyword>
</DOC>